Pall Corporation

High Concentration Monoclonal Antibody Drugs

Manufacturing challenges 



Growth in the formulation of drugs suitable for delivery by subcutaneous injection has highlighted manufacturing challenges. These challenges are associated with the higher concentration of active ingredients required to achieve the low dose volumes delivered to patients.

Manufacturing unit operations that are directly impacted by higher concentration formulations range from ultrafiltration to filtration, filling, and storage.

Solutions that maintain quality, maximize process yield and product recovery are available. They can easily be introduced to adapt an existing manufacturing platform to support the new process requirements.

Download the white paper and learn more about the key manufacturing challenges associated with the development of high concentration monoclonal antibody (mAb) therapies.

Complete the form to get your white paper

Required fields*